Wall Street brokerages forecast that American Renal Associates Holdings Inc (NYSE:ARA) will report $221.35 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $219.70 million and the highest estimate coming in at $223.00 million. American Renal Associates posted sales of $194.38 million in the same quarter last year, which suggests a positive year over year growth rate of 13.9%. The company is expected to issue its next quarterly earnings results on Tuesday, March 5th.
According to Zacks, analysts expect that American Renal Associates will report full-year sales of $849.50 million for the current fiscal year, with estimates ranging from $846.00 million to $853.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $932.50 million, with estimates ranging from $925.00 million to $940.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover American Renal Associates.
American Renal Associates (NYSE:ARA) last posted its quarterly earnings data on Thursday, November 8th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.06. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. The firm had revenue of $211.02 million for the quarter, compared to the consensus estimate of $217.15 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year.
A number of equities research analysts recently commented on ARA shares. Goldman Sachs Group started coverage on American Renal Associates in a research report on Thursday, July 19th. They issued a “neutral” rating and a $16.00 target price on the stock. ValuEngine upgraded American Renal Associates from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. SunTrust Banks reiterated a “buy” rating and issued a $25.00 target price on shares of American Renal Associates in a research report on Thursday, August 9th. Zacks Investment Research upgraded American Renal Associates from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Finally, Leerink Swann upgraded American Renal Associates from a “market perform” rating to an “outperform” rating and upped their target price for the company from $22.00 to $26.00 in a research report on Thursday, August 23rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $22.60.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers purchased a new stake in American Renal Associates in the second quarter valued at approximately $195,000. Macquarie Group Ltd. boosted its position in American Renal Associates by 1,867.7% in the second quarter. Macquarie Group Ltd. now owns 20,700 shares of the company’s stock valued at $326,000 after buying an additional 19,648 shares during the last quarter. Paloma Partners Management Co purchased a new stake in American Renal Associates in the second quarter valued at approximately $356,000. Russell Investments Group Ltd. purchased a new stake in American Renal Associates in the second quarter valued at approximately $405,000. Finally, Engineers Gate Manager LP boosted its position in American Renal Associates by 74.4% in the 3rd quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock worth $496,000 after purchasing an additional 9,764 shares in the last quarter. Hedge funds and other institutional investors own 92.67% of the company’s stock.
ARA opened at $17.50 on Wednesday. American Renal Associates has a 52-week low of $9.91 and a 52-week high of $24.07. The company has a debt-to-equity ratio of 5.30, a quick ratio of 1.04 and a current ratio of 1.07. The stock has a market cap of $667.52 million, a PE ratio of 28.69, a P/E/G ratio of 3.63 and a beta of 2.09.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
See Also: Earnings Per Share
Get a free copy of the Zacks research report on American Renal Associates (ARA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.